10-Q · May 7, 2026
Jade Biosciences reported a significant increase in operating expenses, primarily due to ramped up clinical activities, leading to a net loss of $40.4 million for Q1 2026. Management anticipates that existing cash of…
Earnings analysis · 10-Q
JBIO earnings analysis
Filed August 10, 2026 · Our reading of the company's report
The latest report
Jade remains a clinical-stage biotechnology company with no approved products or product revenue and reported net losses of $55.8 million for the quarter and $96.1 million for the six-month period ended June 30, 2026.…
Read full summary
Jade remains a clinical-stage biotechnology company with no approved products or product revenue and reported net losses of $55.8 million for the quarter and $96.1 million for the six-month period ended June 30, 2026. Liquidity was substantial at $461.2 million of cash, cash equivalents and investments, but management states that additional capital will be required and has authorized up to $200.0 million of potential ATM equity sales. JADE101 advanced into Phase 2 in May 2026, but increasing IgAN competition, clinical execution risk, foreign manufacturing exposure and the absence of numeric financial guidance keep the outlook bearish.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
$461.2M of Cash and Investments
The company reported $107.2 million of cash and cash equivalents and $354.0 million of investments as of June 30, 2026, or $461.2 million in aggregate liquidity.
-
Clinical Investment Continues
Management reported net losses of $55.8 million for the three months ended June 30, 2026 and $96.1 million for the six months ended June 30, 2026.
-
Pipeline Funding Remains the Focus
The accumulated deficit reached $270.5 million as of June 30, 2026, reflecting the company’s ongoing pre-commercial development spending.
-
Additional Capital-Raising Capacity
The company entered into an at-the-market sales agreement on May 7, 2026 allowing potential sales of up to $200.0 million of common stock.
-
JADE101 Advances to Phase 2
The Phase 2 clinical trial of JADE101 in IgA nephropathy was initiated in May 2026, following initiation of its Phase 1 trial in August 2025.
-
Controls Rated Effective
Management concluded that disclosure controls and procedures were effective as of June 30, 2026, and reported no changes in internal control over financial reporting that materially affected or were reasonably likely to materially affect controls during the quarter.
What to watch
-
Future Financing and Dilution
Liquidity remains dependent on future financing: the company states it will require substantial additional funding, while its May 7, 2026 ATM agreement permits up to $200.0 million of equity sales that could dilute stockholders. Existing cash and investments are stated to fund operations for at least twelve months, not indefinitely.
-
Foreign CMO and BIOSECURE Risk
Manufacturing and geopolitical exposure increased through reliance on foreign CROs and CMOs. The filing cites the BIOSECURE Act enacted in December 2025 and warns that designation of a supplier as a biotechnology company of concern, or U.S.-China retaliatory actions, could restrict access to suppliers and delay development.
-
IgAN Competition Is Intensifying
Competitive and regulatory pressure in IgA nephropathy is intensifying: Trutakna received FDA accelerated approval in July 2026 after a reported 42% reduction in UPCR versus placebo, while povetacicept has an FDA PDUFA target action date of November 30, 2026.
Management's outlook
No revenue or EPS guidance was provided in the extracted 10-Q. Management stated that cash and cash equivalents plus investments of $461.2 million as of June 30, 2026 are expected to fund operating expenses and capital expenditure requirements for at least twelve months from issuance of the financial statements; the filing does not provide a quantitative revenue or earnings outlook.
Earlier filings 4
10-K · March 6, 2026
Jade Biosciences is a clinical‑stage immunology biotech focused on engineered anti‑APRIL and B‑cell programs (lead candidate JADE101) designed for less frequent subcutaneous dosing and increased potency. The company has…
10-Q · November 14, 2025
Jade Biosciences reported no product revenue and a net loss of $25,175 (in thousands) for the three months ended September 30, 2025, with GAAP EPS of $(0.48). The company significantly strengthened its liquidity…
10-Q · April 25, 2025
Aerovate reported a materially lower operating loss in Q1 2025 driven by cessation of R&D: total operating expenses fell to $3,387k from $24,618k a year ago, and net loss improved to $2,518k (−$0.09 per share) versus…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.